Estimates Revisions Grace Therapeutics, Inc.
Stocks
GRCE
US00439U1043
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
01:30:00 25/09/2026 am IST
|
5-day change | 1st Jan Change | ||
| 2.160 USD | +1.89% |
|
+1.41% | -37.57% |
| 25/08 | Grace Therapeutics Files for Resale of Up to 4.8 Million Shares | MT |
| 14/08 | Grace Therapeutics, Inc. Reports Impairment charges for the First Quarter Ended June 30, 2026 | CI |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
- Stock Market
- Stocks
- GRCE Stock
- Consensus Grace Therapeutics, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
